ASX Share rice
Sat 15 Aug 2020 - 12:54:am (Sydney)

IMC Share Price

IMMURON LIMITEDIMCPharmaceuticals, Biotechnology & Life Sciences

IMC Company Information

Name:

Immuron Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

62 Lygon Street Carlton Australia 3053

Phone:

61 3 9824 5254

Chief Exec. Officer:

Dr. Jerry Kanellos Ph.D.

Exec. Vice Chairman:

Mr. Peter Anastasiou

CFO & Company Sec.:

Mr. Phillip Allen Hains

Head of Marketing:

Mr. David Lyon

Company Overview:

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease; and IMM-529, a clinical stage product for clostridium difficile infections. The company has a research collaboration with the United States Department of Defense to develop and clinically evaluate a therapeutic against campylobacter. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

IMC Share Price Information

Shares Issued:

220.95M

Market Capitalisation:

$80.65M

Revenue (TTM):

$2.97M

Revenue Per Share (TTM):

$0.02

Earnings per Share:

$-0.032

Profit Margin:

-1.5311

Operating Margin (TTM):

$-1.55

Return On Assets (TTM):

$-0.36

Return On Equity (TTM):

$-0.65

Quarterly Revenue Growth (YOY):

0.591

Gross Profit(TTM):

$1.71M

Diluted Earnings Per Share (TTM):

$-0.028

IMC CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-2,008

Change To Liabilities:

$402.59K

Total Cashflow From Investing Activities:

$-2,008

Net Income:

$-4,632,743

Total Cash From Operating Activities:

$-1,798,579

Depreciation:

$5.29K

Other Cashflow From Investing Activities:

$39

Dividends Paid:

$0

Change To Inventory:

$263.37K

Change To Account Receivables:

$680.34K

Capital Expenditures:

$2.05K

IMC Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-4,632,743

Net Income:

$-4,632,743

Gross Profit:

$1.72M

Operating Income:

$-4,620,766

Other Operating Expenses:

$-532,050

Interest Expense:

$0

Total Revenue:

$2.39M

Total Operating Expenses:

$7.01M

Cost Of Revenue:

$667.37K

IMC Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$1.21M

Total Stockholder Equity:

$7.35M

Other Current Liabilities:

$20.98K

Total Assets:

$8.56M

Common Stock:

$60.51M

Other Current Assets:

$49.29K

Retained Earnings:

$-56,860,523

Other Liabilities:

$14.98K

Other Assets:

$1.86M

Cash:

$5.12M

Total Current Liabilities:

$1.20M

Property - Plant & Equipment:

$17.14K

Net Tangible Assets:

$7.35M

Total Current Assets:

$6.68M

Net Receivables:

$298.93K

Short-Term Investments:

$1.88M

Inventory:

$544.34K

Accounts Payable:

$715.12K

Non Currrent Assets (Other):

$1.86M

Short-Term Investments:

$1.88

Non Current Liabilities Total:

$14.98K

IMC Share Price History

IMC News

23 Jul, 2020
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately US$20.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The Company intends to use the net proceeds from this offering to fund Immuron’s research and development, preclinical and clinical programs, support marketing initiatives surrounding the Company’s flagship product Travelan and provide ongoing working capital for the Company.The Securities and Exchange Commission declared effective a registration statement on Form F-3 (File No. 333-230762) relating to these securities on April 17, 2019. A final prospectus relating to this offering has been filed with the Securities and Exchange Commission. The offering was made only by means of a prospectus. Electronic copies of the final prospectus relating to the offering may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at placements@hcwco.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.This release has been authorised by the directors of Immuron Limited.COMPANY CONTACT:  Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com  INVESTOR RELATIONS: Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 Dave@redchip.com  About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).About Travelan®Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.About Travelers’ diarrheaTravelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.For more information visit: http://www.immuron.comFORWARD-LOOKING STATEMENTS:This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended.  Such statements include, but are not limited to, statements regarding the use of proceeds as well as any statements relating to our growth strategy and product development programs and any other statements that are not historical facts.  Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: market and other conditions, risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
22 Jul, 2020
While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...
21 Jul, 2020
Shares of Immuron Ltd. nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary shares. The offering to "several healthcare-focused institutional investors, which represents about 24% of the ADS outstanding, was priced at $18.75 per ADS. That's below current premarket trading levels, but is 80% above Monday's closing price of $10.41. The stock was up 93% in premarket trading in record territory, but was up as much as 148% earlier. The company had announced earlier that its IMM-124E used to make its gastrointestinal and digestive health immune supplements Travelan and Proectyn demonstrated neutralizing activity against SARS-CoV-2, but that was in "laboratory studies." The stock had run up 63.4% on Monday. It has nearly tripled (up 187%) year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 21.0% and the S&P 500 has gained 0.7%.
MELBOURNE, Australia, July 21, 2020 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studiesImmuron’s technology platform.
20 Jul, 2020
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted.
19 Jun, 2020
Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc. MELBOURNE, Australia, June 19, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders with an update on the progress made to date on the company’s research collaboration with the Naval Medical Research Center (NMRC) previously announced in October 2019.
15 Jun, 2020
In the current session, Immuron Inc. (NASDAQ: IMRN) is trading at $10.30, after a 20.06% spike. Over the past month, the stock increased by 412.50%, and in the past year, by 248.01%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 64.47%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Most often, an industry will prevail in a particular phase of a business cycle, than other industries.Compared to the aggregate P/E ratio of the 0.16 in the Biotechnology industry, Immuron Inc. has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
09 Jun, 2020
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to provide shareholders with an update on the company’s research collaboration with the Naval Medical Research Center (NMRC) to develop and clinically evaluate a new therapeutic against campylobacter and ETEC (E-Coli). The NMRC recently requested a Pre-IND meeting with the U.S. Food and Drug administration (FDA) regarding its new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and ETEC infections.
28 Apr, 2020
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that the cash payments of Board fees will be suspended and replaced with Immuron stock. As announced to the market on 25 March, 2020 the Board and Executive Management reported that significant cost reductions measures have been implemented to preserve the Company’s cash position. As part of these measures, Immuron’s Board of Directors (‘the Board’) have resolved, for the foreseeable future, to relinquish cash payments of fees and in lieu of same receive common stock in the Company.
20 Apr, 2020
Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sales grew by 35% YoY to $475K.
25 Mar, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord Blood Corp (NYSE: CO) * Thermogenesis Holdings Inc (NASDAQ: THMO)(reacted to its fourth-quarter earnings)Down In The Dumps * (Biotech Stocks Hitting 52-week lows on March 24) * Baudax Bio Inc (NASDAQ: BXRX) (reacted to announcement concerning common stock and warrant offerings) * Equillium Inc (NASDAQ: EQ) * IMMURON LTD/S ADR (NASDAQ: IMRN) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) (reacted to an adverse clinical readout ) * Neovasc Inc (NASDAQ: NVCN) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * PLx Pharma Inc (NASDAQ: PLXP) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX)(released its fourth-quarter results) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus T2 Biosystems Licenses COVID-19 Test, Preannounces Q1 Revenue Shortfall, Suspends Guidance T2 Biosystems Inc (NASDAQ: TTOO) said it has entered into a worldwide licensing agreement for a rapid COVID-19 test developed by Center of Discovery and Innovation at Hackensack Meridian Health.Under the agreement, T2 Biosystems will adapt the test to run on its T2Dx Instrument, the same instrument used for the FDA-cleared T2Bacteria and T2Candida Panels.Separately, the company preannounced a revenue shortfall for the first quarter, blaming the predicament on the COVID-19 pandemic, which has disrupted its commercial operations. The company also suspended its guidance for 2020.In after-hours trading, the stock jumped 109.16% to 82 cents.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.PerkinElmer's New Coronavirus Test Gets FDA Emergency Use Authorization PerkinElmer, Inc. (NYSE: PKI) said the FDA has issued Emergency Use Authorization for its new coronavirus RT-PCR test. This will allow clinical labs certified under Clinical Laboratory Improvement Amendments to immediately begin using the kit to detect SARS-CoV-2.In after-hours trading, the stock rose 3.01% to $76.55.Diffusion Pharma Announces Delay In Study of Lead Drug For Stroke Caused By Coronavirus Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) said it expects delays in enrollment in its ambulance-based PHAST-TSC Phase 2 trial in acute stroke due to coronavirus. The LA County Fire Department has suspended future training of first responders who had been scheduled to participate in the trial protocol, the company noted.Immuron Announces Strategic Actions to Tide Over COVID-19 Impact; CEO Steps Down Immuron announced measures to preserve capital, as it navigates through a tough environment amid the COVID-19 outbreak. As a first step, the company announced the resignation of Gary Jacob as CEO and member of the company's board. The company announced the appointment of Jerry Kanellos as CEO, with the move leading to day-to-day control of operations and executive strategy returning to Australia.The company also plans to do away with or significantly reduce external consultant costs and also establish a remuneration model for directors, which will use payment of board fees other than by monetary recompense. These are expected to trim cash operating expense by over $2 million, effective April.Immuron said it will also work toward increasing overall revenues to help mitigate an anticipated decrease in Travelan sales due to decreased travel by promoting Protectyn for gut benefits.Immutep's Immuno-chemotherapy Combo Produces Positive Results In Midstage Breast Cancer Trial Australian biotech IMMUTEP LTD/S ADR (NASDAQ: IMMP) announced data from the Phase 2b AIPAC study that evaluated its lead product candidate eftilagimod alpha in combination with paclitaxel, a taxane standard-of-care chemotherapy, in HER2-negative/HR+ metastatic breast cancer, which showed 63% of patients treated with the combo were progression-free at the 6-month landmark.This compared to 54% for patients who received paclitaxel plus placebo. The company also noted the secondary endpoint of overall response rate increased from 38.4% in the placebo group to 48.3% in the efti group.Allakos Reports Positive Results In Earlystage Study of Drug to Treat Mast Cell Gastrointestinal Disease Allakos Inc (NASDAQ: ALLK) announced positive results from a Phase 1 study that evaluated the safety and efficacy of antolimab in treating patients with mast cell gastrointestinal disease. Six months of treatment resulted in a 64% mean reduction in total symptom score-8, which measures abdominal pain, nausea, vomiting, early satiety, loss of appetite, abdominal cramping, bloating, and diarrhea. Antolimab was also found generally well tolerated, with no drug-related serious adverse events occurring during the study.Separately, the company also announced initiation of three clinical studies of antolimab - a Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis, a Phase 2/3 study in eosinophilic esophagitis, and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers.The stock moved up 1.49% to $60 in after-hours trading.Exelixis' Partner Takeda Gets Regulatory Nod For Cabometyx In Japan For Kidney Cancer Exelixis, Inc. (NASDAQ: EXEL) said Takeda Pharmaceutical Co Ltd (NYSE: TAK), its partner responsible for the clinical development and commercialization of Cabometyx in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market the drug as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma.In pre-market trading, Takeda shares were adding 0.79% to $14.01 and Exelixis shares were moving up 1.01% to $16.01.Earnings Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) reported a net loss of $2.86 per share for the fourth quarter of 2019 compared to a loss of $59.85 per share a year ago. Analysts estimated a loss of $1.49 per share for the quarter.In after-hours trading, the stock slipped 11.62% to 88 cents.Onconova Therapeutics Inc (NASDAQ: ONTX) reported full-year results that showed a loss of $1.49 per share for 2019 compared to a loss of $4.99 per share for 2018. Cash balance at the end of Feb. 2020 stood at $32.6 million. The company expects the cash and cash equivalents to be adequate to fund ongoing trials and operations into the third quarter of 2021.The company also said it has completed the planned enrollment of 360 patients in the INSPIRE trial in higher-risk myelodysplastic syndrome, or MDS, patients. It expects to report topline survival data in the second half of 2020.The stock advanced 14.48% to 42 cents in after-hours trading.On The Radar PDUFA Dates The FDA scheduled to announced its verdict on strong> Bristol-Myers Squibb Co (NYSE: BMY)'s NDA for ozanimod as a treatment option for patients with relapsing forms of multiple sclerosis.Earnings Viela Bio Inc (NASDAQ: VIE) (after the close)Biocept Inc (NASDAQ: BIOC) (after the close)OncoCyte Corp (NYSE: OCX) (after the close)HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close)Eyenovia Inc (NASDAQ: EYEN) (after the close)Exagen Inc (NASDAQ: XGN) (after the close)See more from Benzinga * The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment * The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Company. The keystone of this strategy will be the preservation of capital to allow the Company to weather the current trading conditions pending strengthening of the travel market.
19 Mar, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
03 Mar, 2020
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from.
03 Feb, 2020
Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and.
28 Jan, 2020
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY.
08 Jan, 2020
MELBOURNE, Australia, Jan. 08, 2020 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
21 Nov, 2019
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to.
13 Nov, 2019
The big shareholder groups in Immuron Limited (ASX:IMC) have power over the company. Generally speaking, as a company...